Natera (NASDAQ:NTRA – Free Report) had its price objective lifted by The Goldman Sachs Group from $56.00 to $64.00 in a research note released on Friday morning, Benzinga reports. The brokerage currently has a buy rating on the medical research company’s stock. A number of other equities analysts have also recently issued reports on NTRA. […]
Shares of Natera, Inc. (NASDAQ:NTRA – Get Free Report) have been assigned an average recommendation of “Buy” from the ten brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on […]
Guggenheim initiated coverage on shares of Natera (NASDAQ:NTRA – Free Report) in a research report sent to investors on Thursday morning, MarketBeat reports. The brokerage issued a buy rating and a $70.00 target price on the medical research company’s stock. Other equities analysts have also recently issued research reports about the company. Raymond James upgraded […]
SWS Partners trimmed its holdings in Natera, Inc. (NASDAQ:NTRA – Free Report) by 1.0% in the 2nd quarter, HoldingsChannel reports. The fund owned 79,456 shares of the medical research company’s stock after selling 822 shares during the quarter. Natera makes up approximately 1.2% of SWS Partners’ holdings, making the stock its 14th biggest holding. SWS […]
Braidwell LP boosted its position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 17.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,152,851 shares of the medical research company’s stock after purchasing an additional 170,610 shares during the quarter. Natera accounts for […]